What does a 99.4% purity with a purity figure attached let me conclude?

Details up front: 99.4% · purity figure.

I can parse the result. I am less sure what it licenses me to conclude.

I have deliberately not looked at anyone else’s interpretation yet.

What does this actually establish, and what does it not?

Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Reconciling gross mass to label claim

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

edited 9 Apr 2026 by fib4_reader — clarified the distinction between purity and content

Start from what the detector sees, because that tells you what the number means.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.

The limitation is that single-digit micro-impurities become invisible at typical reporting thresholds, so "no impurities detected" means "none above one in two thousand."

Compare purity within a single laboratory on the same method, never across laboratories.

It helps to be literal here: identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.

Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

If you are ranking vendors, specify a method and have all samples tested at the same place.

On the detail: area percentage is not mass percentage, and conflating the two is the most common misreading of a purity figure.

Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

The underlying point is that purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

Compare purity within a single laboratory on the same method, never across laboratories.